Dan P. Zandberg, MD, on Personalized Immunotherapy for HNSCC: Progress Report

March 06, 2024 By The ASCO Post Staff

Dan P. Zandberg, MD, of UPMC Hillman Cancer Center, discusses study results showing that, although efficacy was low with both nivolumab plus ipilimumab and nivolumab plus relatlimab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC), selected patients had a numerically higher disease control rate, with a longer duration of stable disease (Abstract 4).

Related Content